HK1202433A1 - 用於治療視網膜病症和疾病的 心鈉素 腦鈉素 以及 型利鈉肽 相關肽及其衍生物的方法和用途 - Google Patents

用於治療視網膜病症和疾病的 心鈉素 腦鈉素 以及 型利鈉肽 相關肽及其衍生物的方法和用途

Info

Publication number
HK1202433A1
HK1202433A1 HK15103021.0A HK15103021A HK1202433A1 HK 1202433 A1 HK1202433 A1 HK 1202433A1 HK 15103021 A HK15103021 A HK 15103021A HK 1202433 A1 HK1202433 A1 HK 1202433A1
Authority
HK
Hong Kong
Prior art keywords
natriuretic peptide
cnp
anp
bnp
diseases
Prior art date
Application number
HK15103021.0A
Other languages
English (en)
Inventor
Michael Kozlowski
Original Assignee
Kalos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalos Therapeutics Inc filed Critical Kalos Therapeutics Inc
Publication of HK1202433A1 publication Critical patent/HK1202433A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103021.0A 2011-12-16 2015-03-25 用於治療視網膜病症和疾病的 心鈉素 腦鈉素 以及 型利鈉肽 相關肽及其衍生物的方法和用途 HK1202433A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576720P 2011-12-16 2011-12-16
PCT/US2012/070190 WO2013090931A2 (en) 2011-12-16 2012-12-17 Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases

Publications (1)

Publication Number Publication Date
HK1202433A1 true HK1202433A1 (zh) 2015-10-02

Family

ID=48613379

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103021.0A HK1202433A1 (zh) 2011-12-16 2015-03-25 用於治療視網膜病症和疾病的 心鈉素 腦鈉素 以及 型利鈉肽 相關肽及其衍生物的方法和用途

Country Status (7)

Country Link
US (1) US20150045301A1 (zh)
EP (1) EP2790714A4 (zh)
JP (2) JP2015502368A (zh)
CN (2) CN104039341A (zh)
CA (1) CA2853204A1 (zh)
HK (1) HK1202433A1 (zh)
WO (1) WO2013090931A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JPH10273450A (ja) * 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US20070049251A1 (en) 2005-08-31 2007-03-01 Mock Von A Method and system for wireless communication in emergency situations
CA2698783A1 (en) * 2007-09-11 2009-03-19 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009040083A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100323950A1 (en) * 2007-09-11 2010-12-23 Dorian Bevec Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
CA2698768A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009086516A1 (en) * 2007-12-28 2009-07-09 Kalos Therapeutics, Inc. Anti-proliferative compounds and their use
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AU2010298256B2 (en) * 2009-09-25 2015-08-13 Takeda Pharmaceutical Company Limited Novel NPR-B agonists
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders

Also Published As

Publication number Publication date
CA2853204A1 (en) 2013-06-20
WO2013090931A2 (en) 2013-06-20
JP2018024674A (ja) 2018-02-15
CN108653715A (zh) 2018-10-16
CN104039341A (zh) 2014-09-10
JP2015502368A (ja) 2015-01-22
EP2790714A2 (en) 2014-10-22
EP2790714A4 (en) 2015-08-05
WO2013090931A3 (en) 2013-10-31
US20150045301A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
IL281376A (en) Medicinal peptides of neuregulin for the treatment or prevention of heart failure
IL256004A (en) History of chloropyrazine carboxamide used in the treatment of diseases preferentially in insufficient hydration of the mucosa
HK1215283A1 (zh) 用於調節膽汁酸體內穩態以及治療膽汁酸紊亂和疾病的方法
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
HK1210211A1 (zh) 通過抑制腦源神經營養因子 的天然反義轉錄物治療 相關疾病
HK1202064A1 (zh) 用於皮膚病治療的凱莫瑞 肽的局部製劑
IL215525B (en) Amino acid sequences directed against r6-il and polypeptides containing them for the treatment of diseases and disorders associated with r6-il
IL230510A0 (en) Anti-Lyft peptides and their use in methods for treating diseases and disorders characterized by Lyft
ZA201309557B (en) Methods of treatment for retinal diseases
PH12015501271B1 (en) Stabilized insulin-like growth factor polypeptides
ZA201400167B (en) Treatment of respiratory disorders using trpa1 antagonists
EP2890708A4 (en) PARATHORMONE, INSULIN, AND RELATED PEPTIDES CONJUGATED TO BONE TARGETING FRACTIONS, AND METHODS OF MAKING AND USING THE SAME
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
HK1202433A1 (zh) 用於治療視網膜病症和疾病的 心鈉素 腦鈉素 以及 型利鈉肽 相關肽及其衍生物的方法和用途
EP2925363A4 (en) METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
EP3077412A4 (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
EP2723325A4 (en) NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
EP2773365A4 (en) PEPTIDE ANALOGS FOR THE TREATMENT OF ILLNESSES AND SUFFERING
HK1218373A1 (zh) 用於治療年齡相關失調的重組膠原蛋白 的給予
EP2722389A4 (en) METHOD FOR INCREASING PRODUCTION YIELD OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS